APO Research
Talk to an analyst

APO RESEARCH · REPORT

Janus Kinase inhibitors (JAKi)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Janus Kinase inhibitors (JAKi) Market Outlook and Growth Opportunities 2026

29 December 2025195 pages

Choose your research edition.

Industry ResearchJanus Kinase inhibitors (JAKi) Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Janus Kinase inhibitors (JAKi) Industry Growth and Trends Forecast to 203277 pages · $3,450 USDMarket StructureGlobal Janus Kinase inhibitors (JAKi) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Janus Kinase inhibitors (JAKi) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Janus Kinase inhibitors (JAKi) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Janus Kinase inhibitors (JAKi) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Janus Kinase inhibitors (JAKi) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Janus Kinase inhibitors (JAKi) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Janus Kinase inhibitors (JAKi) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Janus Kinase inhibitors (JAKi) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Janus Kinase inhibitors (JAKi) market include Galapagos NV, AbbVie, Pfizer Inc. and Eli Lilly and Co., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Janus Kinase inhibitors (JAKi) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Janus Kinase inhibitors (JAKi) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Janus Kinase inhibitors (JAKi) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Janus Kinase inhibitors (JAKi) market size, projected growth trends, production technologies, key applications, and end-use industries.

Janus Kinase inhibitors (JAKi) Segment by Company

Galapagos NV

AbbVie

Pfizer Inc.

Eli Lilly and Co.

Janus Kinase inhibitors (JAKi) Segment by Type

Upadacitinib

Tofacitinib

Filgotinib

Baricitinib

Abrocitinib

Janus Kinase inhibitors (JAKi) Segment by Application

Hospital

Clinic

Other

Janus Kinase inhibitors (JAKi) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Janus Kinase inhibitors (JAKi) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Janus Kinase inhibitors (JAKi) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Janus Kinase inhibitors (JAKi) significant trends, drivers, influence factors in global and regions.

6. To analyze Janus Kinase inhibitors (JAKi) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Janus Kinase inhibitors (JAKi) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Janus Kinase inhibitors (JAKi) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Janus Kinase inhibitors (JAKi).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Janus Kinase inhibitors (JAKi) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Janus Kinase inhibitors (JAKi) industry.

Chapter 3: Detailed analysis of Janus Kinase inhibitors (JAKi) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Janus Kinase inhibitors (JAKi) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Janus Kinase inhibitors (JAKi) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Janus Kinase inhibitors (JAKi) Industry Trends Table 2. Janus Kinase inhibitors (JAKi) Industry Drivers Table 3. Janus Kinase inhibitors (JAKi) Industry Opportunities and Challenges Table 4. Janus Kinase inhibitors (JAKi) Industry Restraints Table 5. Global Janus Kinase inhibitors (JAKi) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Janus Kinase inhibitors (JAKi) Revenue Share by Company (2021-2026) Table 7. Global Janus Kinase inhibitors (JAKi) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Janus Kinase inhibitors (JAKi) Sales Volume Share by Company (2021-2026) Table 9. Global Janus Kinase inhibitors (JAKi) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Janus Kinase inhibitors (JAKi) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Janus Kinase inhibitors (JAKi) Key Company Manufacturing Base & Headquarters Table 12. Global Janus Kinase inhibitors (JAKi) Company, Product Type & Application Table 13. Global Janus Kinase inhibitors (JAKi) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Janus Kinase inhibitors (JAKi) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Upadacitinib Table 18. Significant Companies of Tofacitinib Table 19. Significant Companies of Filgotinib Table 20. Significant Companies of Baricitinib Table 21. Significant Companies of Abrocitinib Table 22. Global Janus Kinase inhibitors (JAKi) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Janus Kinase inhibitors (JAKi) Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Janus Kinase inhibitors (JAKi) Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Janus Kinase inhibitors (JAKi) Sales Volume Share by Type (2021-2026) Table 26. Global Janus Kinase inhibitors (JAKi) Sales Volume Share by Type (2027-2032) Table 27. Global Janus Kinase inhibitors (JAKi) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Janus Kinase inhibitors (JAKi) Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Janus Kinase inhibitors (JAKi) Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Janus Kinase inhibitors (JAKi) Sales Value Share by Type (2021-2026) Table 31. Global Janus Kinase inhibitors (JAKi) Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Other Table 35. Global Janus Kinase inhibitors (JAKi) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Janus Kinase inhibitors (JAKi) Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Janus Kinase inhibitors (JAKi) Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Janus Kinase inhibitors (JAKi) Sales Volume Share by Application (2021-2026) Table 39. Global Janus Kinase inhibitors (JAKi) Sales Volume Share by Application (2027-2032) Table 40. Global Janus Kinase inhibitors (JAKi) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Janus Kinase inhibitors (JAKi) Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Janus Kinase inhibitors (JAKi) Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Janus Kinase inhibitors (JAKi) Sales Value Share by Application (2021-2026) Table 44. Global Janus Kinase inhibitors (JAKi) Sales Value Share by Application (2027-2032) Table 45. Global Janus Kinase inhibitors (JAKi) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Janus Kinase inhibitors (JAKi) Sales by Region (2021-2026) & (K Units) Table 47. Global Janus Kinase inhibitors (JAKi) Sales Market Share by Region (2021-2026) Table 48. Global Janus Kinase inhibitors (JAKi) Sales by Region (2027-2032) & (K Units) Table 49. Global Janus Kinase inhibitors (JAKi) Sales Market Share by Region (2027-2032) Table 50. Global Janus Kinase inhibitors (JAKi) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Janus Kinase inhibitors (JAKi) Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Janus Kinase inhibitors (JAKi) Sales Value Share by Region (2021-2026) Table 53. Global Janus Kinase inhibitors (JAKi) Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Janus Kinase inhibitors (JAKi) Sales Value Share by Region (2027-2032) Table 55. Global Janus Kinase inhibitors (JAKi) Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Janus Kinase inhibitors (JAKi) Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Janus Kinase inhibitors (JAKi) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Janus Kinase inhibitors (JAKi) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Janus Kinase inhibitors (JAKi) Sales by Country (2021-2026) & (K Units) Table 60. Global Janus Kinase inhibitors (JAKi) Sales Market Share by Country (2021-2026) Table 61. Global Janus Kinase inhibitors (JAKi) Sales by Country (2027-2032) & (K Units) Table 62. Global Janus Kinase inhibitors (JAKi) Sales Market Share by Country (2027-2032) Table 63. Global Janus Kinase inhibitors (JAKi) Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Janus Kinase inhibitors (JAKi) Sales Value Market Share by Country (2021-2026) Table 65. Global Janus Kinase inhibitors (JAKi) Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Janus Kinase inhibitors (JAKi) Sales Value Market Share by Country (2027-2032) Table 67. Galapagos NV Company Information Table 68. Galapagos NV Business Overview Table 69. Galapagos NV Janus Kinase inhibitors (JAKi) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Galapagos NV Janus Kinase inhibitors (JAKi) Product Portfolio Table 71. Galapagos NV Recent Development Table 72. AbbVie Company Information Table 73. AbbVie Business Overview Table 74. AbbVie Janus Kinase inhibitors (JAKi) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. AbbVie Janus Kinase inhibitors (JAKi) Product Portfolio Table 76. AbbVie Recent Development Table 77. Pfizer Inc. Company Information Table 78. Pfizer Inc. Business Overview Table 79. Pfizer Inc. Janus Kinase inhibitors (JAKi) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Pfizer Inc. Janus Kinase inhibitors (JAKi) Product Portfolio Table 81. Pfizer Inc. Recent Development Table 82. Eli Lilly and Co. Company Information Table 83. Eli Lilly and Co. Business Overview Table 84. Eli Lilly and Co. Janus Kinase inhibitors (JAKi) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Eli Lilly and Co. Janus Kinase inhibitors (JAKi) Product Portfolio Table 86. Eli Lilly and Co. Recent Development Table 87. Key Raw Materials Table 88. Raw Materials Key Suppliers Table 89. Janus Kinase inhibitors (JAKi) Distributors List Table 90. Janus Kinase inhibitors (JAKi) Customers List Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Janus Kinase inhibitors (JAKi) Product Image Figure 2. Global Janus Kinase inhibitors (JAKi) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Janus Kinase inhibitors (JAKi) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Janus Kinase inhibitors (JAKi) Sales (2021-2032) & (K Units) Figure 5. Global Janus Kinase inhibitors (JAKi) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Janus Kinase inhibitors (JAKi) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Upadacitinib Image Figure 10. Tofacitinib Image Figure 11. Filgotinib Image Figure 12. Baricitinib Image Figure 13. Abrocitinib Image Figure 14. Global Janus Kinase inhibitors (JAKi) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Janus Kinase inhibitors (JAKi) Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Janus Kinase inhibitors (JAKi) Sales Volume Share by Type (2021-2032) Figure 17. Global Janus Kinase inhibitors (JAKi) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Janus Kinase inhibitors (JAKi) Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Janus Kinase inhibitors (JAKi) Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Other Image Figure 23. Global Janus Kinase inhibitors (JAKi) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Janus Kinase inhibitors (JAKi) Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Janus Kinase inhibitors (JAKi) Sales Volume Share by Application (2021-2032) Figure 26. Global Janus Kinase inhibitors (JAKi) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Janus Kinase inhibitors (JAKi) Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Janus Kinase inhibitors (JAKi) Sales Value Share by Application (2021-2032) Figure 29. Global Janus Kinase inhibitors (JAKi) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Janus Kinase inhibitors (JAKi) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Janus Kinase inhibitors (JAKi) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Janus Kinase inhibitors (JAKi) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Janus Kinase inhibitors (JAKi) Sales Value (2021-2032) & (US$ Million) Figure 34. North America Janus Kinase inhibitors (JAKi) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Janus Kinase inhibitors (JAKi) Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Janus Kinase inhibitors (JAKi) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Janus Kinase inhibitors (JAKi) Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Janus Kinase inhibitors (JAKi) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Janus Kinase inhibitors (JAKi) Sales Value (2021-2032) & (US$ Million) Figure 40. South America Janus Kinase inhibitors (JAKi) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Janus Kinase inhibitors (JAKi) Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Janus Kinase inhibitors (JAKi) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Janus Kinase inhibitors (JAKi) Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Janus Kinase inhibitors (JAKi) Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Upadacitinib
  • Tofacitinib
  • Filgotinib
  • Baricitinib
  • Abrocitinib
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Galapagos NV
  • AbbVie
  • Pfizer Inc.
  • Eli Lilly and Co.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Janus Kinase inhibitors (JAKi) Sales Value (2021-2032)
  4. 1.2.2 Global Janus Kinase inhibitors (JAKi) Sales Volume (2021-2032)
  5. 1.2.3 Global Janus Kinase inhibitors (JAKi) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Janus Kinase inhibitors (JAKi) Market Dynamics
  1. 2.1 Janus Kinase inhibitors (JAKi) Industry Trends
  2. 2.2 Janus Kinase inhibitors (JAKi) Industry Drivers
  3. 2.3 Janus Kinase inhibitors (JAKi) Industry Opportunities and Challenges
  4. 2.4 Janus Kinase inhibitors (JAKi) Industry Restraints
3 Janus Kinase inhibitors (JAKi) Market by Company
  1. 3.1 Global Janus Kinase inhibitors (JAKi) Company Revenue Ranking in 2025
  2. 3.2 Global Janus Kinase inhibitors (JAKi) Revenue by Company (2021-2026)
  3. 3.3 Global Janus Kinase inhibitors (JAKi) Sales Volume by Company (2021-2026)
  4. 3.4 Global Janus Kinase inhibitors (JAKi) Average Price by Company (2021-2026)
  5. 3.5 Global Janus Kinase inhibitors (JAKi) Company Ranking (2024-2026)
  6. 3.6 Global Janus Kinase inhibitors (JAKi) Company Manufacturing Base and Headquarters
  7. 3.7 Global Janus Kinase inhibitors (JAKi) Company Product Type and Application
  8. 3.8 Global Janus Kinase inhibitors (JAKi) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Janus Kinase inhibitors (JAKi) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Janus Kinase inhibitors (JAKi) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Janus Kinase inhibitors (JAKi) Market by Type
  1. 4.1 Janus Kinase inhibitors (JAKi) Type Introduction
  2. 4.1.1 Upadacitinib
  3. 4.1.2 Tofacitinib
  4. 4.1.3 Filgotinib
  5. 4.1.4 Baricitinib
  6. 4.1.5 Abrocitinib
  7. 4.2 Global Janus Kinase inhibitors (JAKi) Sales Volume by Type
  8. 4.2.1 Global Janus Kinase inhibitors (JAKi) Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Janus Kinase inhibitors (JAKi) Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Janus Kinase inhibitors (JAKi) Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Janus Kinase inhibitors (JAKi) Sales Value by Type
  12. 4.3.1 Global Janus Kinase inhibitors (JAKi) Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Janus Kinase inhibitors (JAKi) Sales Value by Type (2021-2032)
  14. 4.3.3 Global Janus Kinase inhibitors (JAKi) Sales Value Share by Type (2021-2032)
5 Janus Kinase inhibitors (JAKi) Market by Application
  1. 5.1 Janus Kinase inhibitors (JAKi) Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Janus Kinase inhibitors (JAKi) Sales Volume by Application
  6. 5.2.1 Global Janus Kinase inhibitors (JAKi) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Janus Kinase inhibitors (JAKi) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Janus Kinase inhibitors (JAKi) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Janus Kinase inhibitors (JAKi) Sales Value by Application
  10. 5.3.1 Global Janus Kinase inhibitors (JAKi) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Janus Kinase inhibitors (JAKi) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Janus Kinase inhibitors (JAKi) Sales Value Share by Application (2021-2032)
6 Janus Kinase inhibitors (JAKi) Regional Sales and Value Analysis
  1. 6.1 Global Janus Kinase inhibitors (JAKi) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Janus Kinase inhibitors (JAKi) Sales by Region (2021-2032)
  3. 6.2.1 Global Janus Kinase inhibitors (JAKi) Sales by Region: 2021-2026
  4. 6.2.2 Global Janus Kinase inhibitors (JAKi) Sales by Region (2027-2032)
  5. 6.3 Global Janus Kinase inhibitors (JAKi) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Janus Kinase inhibitors (JAKi) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Janus Kinase inhibitors (JAKi) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Janus Kinase inhibitors (JAKi) Sales Value by Region (2027-2032)
  9. 6.5 Global Janus Kinase inhibitors (JAKi) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Janus Kinase inhibitors (JAKi) Sales Value (2021-2032)
  12. 6.6.2 North America Janus Kinase inhibitors (JAKi) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Janus Kinase inhibitors (JAKi) Sales Value (2021-2032)
  15. 6.7.2 Europe Janus Kinase inhibitors (JAKi) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Janus Kinase inhibitors (JAKi) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Janus Kinase inhibitors (JAKi) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Janus Kinase inhibitors (JAKi) Sales Value (2021-2032)
  21. 6.9.2 South America Janus Kinase inhibitors (JAKi) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Janus Kinase inhibitors (JAKi) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Janus Kinase inhibitors (JAKi) Sales Value Share by Country, 2025 VS 2032
7 Janus Kinase inhibitors (JAKi) Country-level Sales and Value Analysis
  1. 7.1 Global Janus Kinase inhibitors (JAKi) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Janus Kinase inhibitors (JAKi) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Janus Kinase inhibitors (JAKi) Sales by Country (2021-2032)
  4. 7.3.1 Global Janus Kinase inhibitors (JAKi) Sales by Country (2021-2026)
  5. 7.3.2 Global Janus Kinase inhibitors (JAKi) Sales by Country (2027-2032)
  6. 7.4 Global Janus Kinase inhibitors (JAKi) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Janus Kinase inhibitors (JAKi) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Janus Kinase inhibitors (JAKi) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Janus Kinase inhibitors (JAKi) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Janus Kinase inhibitors (JAKi) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Janus Kinase inhibitors (JAKi) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Galapagos NV
  2. 8.1.1 Galapagos NV Company Information
  3. 8.1.2 Galapagos NV Business Overview
  4. 8.1.3 Galapagos NV Janus Kinase inhibitors (JAKi) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Galapagos NV Janus Kinase inhibitors (JAKi) Product Portfolio
  6. 8.1.5 Galapagos NV Recent Developments
  7. 8.2 AbbVie
  8. 8.2.1 AbbVie Company Information
  9. 8.2.2 AbbVie Business Overview
  10. 8.2.3 AbbVie Janus Kinase inhibitors (JAKi) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Janus Kinase inhibitors (JAKi) Product Portfolio
  12. 8.2.5 AbbVie Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Janus Kinase inhibitors (JAKi) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Janus Kinase inhibitors (JAKi) Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 Eli Lilly and Co.
  20. 8.4.1 Eli Lilly and Co. Company Information
  21. 8.4.2 Eli Lilly and Co. Business Overview
  22. 8.4.3 Eli Lilly and Co. Janus Kinase inhibitors (JAKi) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly and Co. Janus Kinase inhibitors (JAKi) Product Portfolio
  24. 8.4.5 Eli Lilly and Co. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Janus Kinase inhibitors (JAKi) Value Chain Analysis
  2. 9.1.1 Janus Kinase inhibitors (JAKi) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Janus Kinase inhibitors (JAKi) Sales Mode & Process
  6. 9.2 Janus Kinase inhibitors (JAKi) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Janus Kinase inhibitors (JAKi) Distributors
  9. 9.2.3 Janus Kinase inhibitors (JAKi) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst